Table 3.
Association between postnatal CMV infection and secondary outcomes
| Outcome | Postnatal CMV+ | Postnatal CMV- | Relative risk* (95% CI) | P value |
| Death | 3/33 (9.1%) | 28/563 (5.0%) | 1.78 (0.64, 4.94) | 0.27 |
| NEC | 6/33 (18%) | 37/563 (6.6%) | † | |
| BPD (mild, moderate or severe) | 14/33 (42%) | 226/563 (40%) | 1.00 (0.69 to 1.46) | 0.98 |
| BPD (moderate or severe) | 8/33 (24%) | 128/563 (23%) | 1.02 (0.57 to 1.80) | 0.95 |
| ROP (stage 2+) | 4/33 (12%) | 76/563 (13%) | 0.85 (0.34 to 2.09) | 0.72 |
| ROP (stage 3+) | 1/33 (3.0%) | 22/563 (3.9%) | 0.73 (0.10 to 5.21) | 0.75 |
| Positive blood culture | 5/33 (15%) | 59/563 (10%) | 1.36 (0.68 to 2.74) | 0.38 |
| Composite outcome‡ | 12/33 (36%) | 171/563 (30%) | 1.14 (0.77 to 1.69) | 0.51 |
*Results from modified Poisson regression models adjusted for birth weight and centre.
†Please refer to table 2 for estimates of risk for NEC, accounting for temporality between exposure and outcome.
‡Defined as death, moderate or severe BPD, ROP stage 3+or NEC.
BPD, bronchopulmonary dysplasia; CMV, cytomegalovirus; NEC, necrotising enterocolitis; ROP, retinopathy of prematurity.